• Home
  • CML Experts
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • Other CML experts in America >
      • Other CML experts in Canada >
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connies Eaves
        • Dr. Josée Hébert
        • Dr. Pierre Laneuville
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Luigina Mollica
      • Other CML experts in US >
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Rey Garcia, RN, BSN
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Arul Chinnaiyan
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Frank Giles
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Karen Seiter
        • Dr. Neil Shah
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Bin Zhang
    • Other CML Experts in Europe >
      • Dr. Jane Apperley
      • Dr. Michele Baccarani
      • Pr. Agnès Buzyn
      • Dr. Gabriel Etienne
      • Dr. Marie-Joëlle Mozziconacci
      • Dr. François Guilhot
      • Dr. Eliane Gluckman
      • Dr. Andreas Hochhaus
      • Dr. Stephen O'Brien
      • Stéphane Prost
      • Dr. Tessa L Holyoake
      • Dr. Hana Klamova
      • Dr. Jeroen J.W.M. Janssen
      • Dr. Franck-Emmanuel Nicolini
      • Dr. Delphine Rea
      • Dr. Johan Richter
      • Dr. Philippe Rousselot
      • Dr. Giuseppe Saglio
      • Dr. François-Xavier Mahon
      • Pr Gregor Verhoef
    • Other CML experts in Asia >
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • Other CML experts in Africa >
      • Dr. Anthony Oyekunle
    • Other CML experts in Australia >
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • Introduction to CML
    • Blood
    • Bone Marrow
    • DNA
    • Immune System >
      • Natural killer cell - NK
      • T Cells
    • JAK2 Gene
    • Treatment response in CML
    • Polymerase Chain Reaction >
      • Dr. Kary Bank Mullis
    • Stem Cells
    • Donor lymphocyte infusion (DLI)
    • Blood-Brain Barrier
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Gleevec (Imatinib)
    • Tasigna (Nilotinib)
    • Sprycel (Dasatinib)
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • ABL001 (Asciminib)
    • Synribo (Omacetaxine )
    • Jakafi (Ruxolitinib)
    • (Bafetinib)
    • (Danusertib)
    • (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • BP1001
    • K0706
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Skin
      • Weight gain
    • CML and Nutrition
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Music therapy >
        • YouTube creation by CMLer's family
        • Magnificent (I Believe)
        • Adagio for Strings (Samuel Barber)
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • Virginia Garner
    • Pat Elliott
    • Jan Geissler
    • Kris
    • Nigel
    • Katie
    • Tamera Simonson
    • Hans Loland
    • Alyssa
    • Brown Dudley
    • Erin Havel (Author)
    • Erin Zammett Ruddy
    • Rob Shick
    • Gary Gonzales
    • Ron Robbecke
    • Drew Johnston
    • Angela Tyrrell
    • Doug Jenson
    • Rich Jones
    • Kevin Williams
    • Jean McGlynn
    • Austin Granatowicz
    • Tom Cleaver
    • Others testimonials
    • Some celebrities >
      • Alexa Score
      • Laura Boyd
      • Dr. Richard Rockefeller
      • Tim Holcomb
      • Doris Muramatsu
      • Ryan O'Neal
      • Charlie Schlatter
      • Kelvin Alston
      • Kareem Abdul-Jabar
      • Jason Blake
      • Brian Boyle
      • Roman Reigns
      • Rick Upchurch
    • Bud Romine - the first patient
    • Kayla Naton (Pregnancy)
    • Suzan Mc Namara and the petition
  • Blogs
    • Access CML Drugs
    • Trey's CML Leukemia Blog
    • Living with CML
    • CMKID's blog – Dislodging the bullet
    • CML Recovery - Stopping KTI
    • Hans's Blog
    • Elizabeth's Blog - my leukemia journey
    • Elizabeth's Blog - Heart of the rose
    • Ian's Blog
    • Joe's Blog
    • Jon's Blog
    • Josh's Blog
    • Mannan's Blog
    • Justin Ozuna's Blog
    • Lindsey's Blog
    • Matt's Blog
    • Matthew's Blog
    • Michelle's Blog
    • Michelle D's Blog
    • Nayree's Blog
    • Rob's Blog
  • News on CML (Chronic myeloid leukemia)
    • English
    • English- Archives 2017-2016
    • English - Archives 2015-2001
    • French (Français)
    • Spanish (Español)
  • Various topics
    • You’ve just been diagnosed
    • History of CML
    • Cure possible for CML? >
      • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
      • Inhibition of the protein Ezh2 can cure CML?
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
      • Inhibition of STAT5 in conjunction with standard TKI therapy
      • CML vaccine
      • Can immunotherapy cure leukemia?
      • Chimeric Antigen Receptor T-Cell Therapy
      • Can genetic sequencing help to cure leukemia?
      • Natural Medicine >
        • Possible cure for CML in Fish Oil
        • Betel leaf may help fight CML
        • Feverfew extract (parthenolide)
        • Can dandelions kill cancer?
        • Can curcumin cure leukemia?
      • Can the new drug CX-5461 cure leukemia?
      • CRISPR-Cas9 gene-editing technique
      • Presence of bcr abl fusion transcripts in healthy individua
      • Math could help cure leukemia
    • Treatment free remission (TFR ) >
      • The French trial called STIM (Stop Imatinib)
      • De-escalation of treatment
    • CML causes
    • CML and pregnancy
    • Children with CML
    • Food and Drug Interactions
    • Bone marrow transplant
    • CML Blast Crisis treatment
    • Stem cells from umbilical cord blood
    • Mutation T315I
    • Sensitive detection of BCR-ABL1 mutations
    • Elderly patients with CML
    • Living with CML and diabetes
    • Non-adherence of CML patients
    • Vaccination of CMLers
    • Sports with CML
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • CML Awareness Day
    • The movie "Dying to Survive"
  • Congresses, conferences, meetings ASH, ASCO, EHA ...
    • ASCO - American Society of Clinical Oncology >
      • ASCO 2018 - Chicago
      • ASCO 2017 - Chicago
      • ASCO 2016 - Chicago
      • ASCO 2015 - Chicago
      • ASCO 2014 - Chicago
      • ASCO 2013 - Chicago
      • ASCO 2012 - Chicago
      • ASCO 2011 - Chicago
      • ASCO 2010 - Chicago
    • ASH - American Society of Hematology >
      • ASH 2018 - San Diego
      • ASH 2017 - Atlanta
      • ASH 2016 - San Diego
      • ASH 2015 - Orlando
      • ASH 2014 - San Francisco
      • ASH 2013 - New Orleans
      • ASH 2012 - Atlanta
      • ASH 2011 - San Diego
      • ASH 2010 - Orlando
      • ASH 2009 - New Orleans
    • BTG - Bridging the Gap >
      • BTG 2011 - Singapore (Singapore)
    • CML & MPDs - UK National Meetings
    • CML Horizons >
      • CML Horizon 2018 -Warsaw (Pologna)
      • CML Horizon 2017- Frankfurt (Germany)
      • CML Horizon 2016 - Ljubljana (Slovenia)
      • CML Horizons 2015 - (Barcelona, Spain)
      • CML Horizons 2014 - ( Belgrade, Serbia)
      • CML Horizons 2013 - (Prague - Czech Republic)
      • CML Horizons 2012 - (Munich, Germany)
      • CML Horizons 2011 - (Amsterdam - The Netherlands)
    • EHA - European Hematology Association >
      • EHA 2018 - Stockholm(Sweden)
      • EHA 2017 - Madrid (Spain)
      • EHA2016-Copenhagen,(Denmark)
      • EHA 2015 - Vienne (Austria)
      • EHA 2014 - Milan (Italy)
      • EHA 2013 - Stockholm (Sweden)
      • EHA 2012 - Amsterdam (The Netherlands)
      • EHA 2011 - London (England)
      • EHA 2010 - Cascais (Portugal)
      • EHA 2009 - Berlin (Germany)
      • EHA 2008 - Copenhague (Danemark)
    • ESH - European School of Haematology >
      • ESH 2016 - Houston - USA
      • ESH 2015 - Estoril - Portugal
      • ESH 2014 - Philadelphia
  • Educational videos
    • Educational videos (in English)
    • Educación de vídeos en español (in Spanish)
    • Vidéos pédagogiques en français (in French)
  • Educational events
  • CML Glossaries
  • Professionnel help and literature
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Patient Rights
  • Moral Support
    • Where to get help and support
    • Family support
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • The march toward healing
    • Be happy
    • Dances at the Cancer Research Centre
    • The spoon theory
    • Stronger
    • Magnificent - Beauty of nature
  • Links to other sites, forums and Facebook
    • Sites ( English and other languages)
    • Forums
    • CML on Facebook
    • CML on Twitter
    • Audio Podcast
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • About us
    • Guestbook
    • Contact us
Chronic Myeloid Leukemia

Sprycel (dasatinib)  -  CML  -   Chronic Myeloid Leukemia

''Dasatinib, also known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibband sold under the trade name Sprycel®. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitorapproved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastaticmelanoma.
The drug is named after one of the inventor chemists,
Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.''
Extract of  
Wikipedia

SITES 
Sprycel®

FORUMS    

CMLSupport (discussions about Sprycel
®)

LLS    Sprycel® and irritability
LLS    Sprycel® Side Effect - Advice appreciated
LLS    Sprycel® (Dasatinib) Unresolved/Permanent skin issues

 ​
VIDEOS

What are the efficacy and safety considerations of dasatinib therapy?
April 29, 2016, MediCom Oncology

Sprycel
®(dasatinib) in the Second-Line Setting
February 17, 2015, OncLiveTV

Sprycel
®, a new medication for CML – Dr Lipton
March 28, 2007, For Your Life



ARTICLES

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
December 27, 2018, Journal of Hematology & Oncology

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
August 9, 2018, PubMed

Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
August 2018, Springer Link

EC approves expanded indication for Sprycel
July 6, 2018, thepharmaletter

Dasatinib Approved in Europe for Pediatric Ph+ Chronic Phase CML
July 5, 2018,  OncLive

Maintenance therapy with dasatinib administrated every other day in patients with chronic myeloid leukemia
May 17, 2018, EHA 2018

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
May 3, 2018,  PubMed

Dasatinib: A Safe and Effective Option for Pediatric CML
March 5, 2018, Cancer Therapy Advisor

Dasatinib dose management for the treatment of chronic myeloid leukemia
January 25, 2018, Cancer

Pepsi® or Coke®? Influence of acid on dasatinib absorption
January 1, 2018, PublMed


Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)
December 2017, 
ASH 2017
​
 ​
Dasatinib Induced Reversible Nephrotic Range Proteinuria Occurs More Frequently Compared to Other Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
​
December 2017, 
ASH 2017
 
Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)

December 2017, ASH 2017

Interim Results of the Canadian Tyrosine Kinase Inhibitor
Discontinuation Trial for 2nd Attempt of Treatment Free Remission: Treatment Free Remission Accomplished By Dasatinib (TRAD)

December 2017, ASH 2017

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal

New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment
June 3, 2016, NCBI

Newer Generation TKIs May Be More Effective Than Imatinib for CP-CML
March 30, 2016 , Cancer Therapy Advisor

Dasatinib Commonly Induces Lymphocytosis in CML Patients
March 29, 2016, CancerNetwork

What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
February 2016, PublMed

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients
December 7, 2015, ASH 2015

Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias
December 7, 2015, ASH 2015

Velocity of Early BCR-ABL Transcript Elimination As an Optimized Predictor of Deep Molecular Response in Chronic Myeloid Leukemia Patients in Chronic Phase on Treatment with Dasatinib
December 7, 2015, ASH 2015

Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib
December 7, 2015, ASH 2015

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
December 5, 2015, ASH 2015

Bristol-Myers Leukemia Drug Sprycel®'s US Label Updated
August 14, 2015,  Yahoo News

FDA Approves Labeling Update to Include New Sprycel
® Data
August 13, 2015,  Cancer Therapy Advisor

An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML)  
June 2, 2014, 2014 ASCO Annual Meeting


Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study
February 14, 2014, Blood Journal


Efficacy and safety of dasatinib versus  imatinib in the East Asian subpopulation of the DASISION trial of newly  diagnosed chronic myeloid leukemia in chronic phase
December 2013, DocGuide.com

Dasatinib Shows  Promise for Pediatric CML, ALL  Patients
September 13, 2013, Cancer  Network

Impressive thrombocytosis evolving in a  patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional  JAK2V617F
September 5, 2013, Experimental Hematology &  Oncology


Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
April 2013, Research  Gate

Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
October 29, 2012,  PublMed

A trial of dasatinib and BMS-833923 for chronic myeloid  leukaemia (CA180323)
October 22, 2012,  Cancer Research  UK

Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus
October 1, 2012, PublMed

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by  dasatinib.
September 15, 2012,  PublMed

Dasatinib Achieves Higher Response Rate Than Imatinib in CML
September 6, 2012, Cancer Network


Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first line dasatinib   
May 29, 2012, Journal Blood

Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives
January 15, 2012, PubLMed

Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells
December 19, 2011,
Nature

FDA Drug Safety Communication: Sprycel
® (dasatinib) and risk of pulmonary arterial hypertension
November 10, 2011, U.S. Food and Drug Administration


Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
July 1, 2011, European Respiratory Journal


Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011,  2011 ASCO Annual Meeting

Dasatinib Shows Superior Efficacy and Acceptable Tolerability, Supporting First-Line Use in Newly Diagnosed CML-CP
June 3 , 2011,  Monthly Prescribing Reference

FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
October 28, 2010, FierceBiotech

Dasatinib, an immodulator?
August 2010, Journal Blood


Pleural effusions due to dasatinib
July 16, 2010, PublMed

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia - Dasatinib is associated with increased risk of bleeding
July 9, 2009, Journal Blood

Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday

Dasatinib suppresses in vitro natural killer cell cytotoxicity
April 15, 2008, Journal Blood

Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
April 8, 2008, PublMed


Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia
October 15, 2007, American Journal of Respiratory and Critical Care Medicine

Dasatinib effective in treating resistant CML cases
January 21, 2006,  The Pharmaceutical Journal



          (See our disclaimer - Voir notre avis de non-responsabilité- Vea nuestro aviso legal).

Copyright © 2010-2019 CMLeukemia.com
DMCA.com Protection Status